1
72
X. Nie et al. / Journal of Molecular Catalysis A: Chemical 393 (2014) 171–174
O
128.1, 127.5, 127.0, 73.4, 71.5, 71.1, 59.3, 21.0, 20.9. Enantiomeric
R3
ratio was determined by HPLC using Chiracel OJ-RH column after
reduction with NaBH /MeOH (80:20 MeOH/H O, 1 mL/min flow
1
2
3
+
a: R =R =R =Me;
Ph3P
O
N
1
2
3
4
2
R2
b: R =R =Me, R =n-Bu;
PF -
HN
1
2
3
rate), endo isomers tR = 8.5 min (major enantiomer) and 10.0 min
minor enantiomer).
4S, 5R)-2-Benzyl-4-formyl-5-methyl-3-(2-napthyl) isoxazo-
6
c: R =H, R =C(CH ), R =Me.
R1
3
(
1
(
−
1
Fig. 1. Structure of the tetraarylphosphonium supported chiral imidazolidinones.
lidine (2e): IR (NaCl): ꢀ 2866, 1723, 1601, 1496, 1454, 1125 cm
H NMR (600 MHz, CDCl , ppm): ı 9.72 (d, J = 1.9 Hz, 1H, CHO),
;
1
3
7
.77–7.20 (m, 12H, ArH), 4.52–4.48 (m, 1H, CHON), 4.24 (d, J = 7.9 Hz,
E-crotonaldehyde (2.5 mL, 30 mmol) was added, and then the mix-
ture was stirred for 36 h at this temperature. The resulting solution
was then evaporated under vacuum. The residue was dissolved in
the minimum amount of CH Cl (2 mL) and poured in Et O (25 mL),
and then filtered. The filtrate was concentrated under vacuum and
purified by silica gel column chromatography (n-hexane/EtOAc,
1H, CHNO), 3.96 (d, J = 14.3 Hz, 1H, C H5CH ), 3.80 (d, J = 14.3 Hz,
6
2
1H, C H5CH ), 3.13–3.10 (m, 1H, CHCHO), 1.45 (d, J = 6.2 Hz, 3H,
6
2
1
3
OCHCH ); C NMR (150 MHz, CDCl , ppm): ı 198.4, 137.1, 135.8,
3
3
133.4, 133.2, 128.9, 128.6, 128.2, 127.9, 127.7, 127.2, 126.9, 126.4,
126.2, 124.9, 73.7, 71.5, 71.3, 59.7, 20.9. Enantiomeric ratio was
determined by HPLC using Chiracel OJ-RH column after reduc-
tion with NaBH /MeOH (70:30 MeOH/H O, 1 mL/min flow rate),
2
2
2
5
0:1, v/v) to afford the desired products, in which the endo/exo
4
2
1
ratio was determined by H NMR. The precipitate in the sand-core
funnel was dried under vacuum and reused in further reactions as
the recovered catalyst. The recovered catalyst was examined by H
endo isomers tR = 69.7 min (major enantiomer) and 76.0 min (minor
enantiomer).
1
(4S, 5R)-2-Benzyl-4-formyl-5-propyl-3-phenylisoxazolidine
−
1
NMR spectroscopy, which showed unchanged after each recovery.
Spectroscopic data of the 1,3-dipolar cycloaddition products:
(2f): IR (NaCl): ꢀ 2872, 1725, 1495, 1455, 1377, 1047 cm
;
1
H NMR (400 MHz, CDCl , ppm): ı 9.70 (d, J = 2.6 Hz, 1H, CHO),
3
(4S,
5R)-2-Benzyl-5-methyl-3-phenylisoxazolidine-4-
7.35–7.13 (m, 10H, ArH), 4.29–4.21 (m, 1H, CHCH CH CH ), 4.06 (d,
2
2
3
carbaldehyde (2a): IR (NaCl): ꢀ 2928, 1720, 1603, 1495, 1455,
J = 7.8 Hz, 1H, C H5CH), 3.93 (d, J = 14.3 Hz, 1H, C H5CH ), 3.74 (d,
6
6
2
−
1
1
1
373 cm
;
H NMR (400 MHz, CDCl , ppm): ı 9.71 (d, J = 2.3 Hz,
J = 14.3 Hz, 1H, C H5CH ), 3.08–3.04 (m, 1H, CHCHO), 1.94–1.85 (m,
3
6 2
1
H, CHO), 7.37–7.15(m, 10H, ArH), 4.49–4.46 (m, 1H, CHCH ), 4.10
1H, CHCH CH CH ), 1.60–1.54 (m, 1H, CHCH CH CH ), 1.40–1.24
3
2
2
3
2
2
3
13
(
d, J = 7.8 Hz, 1H, C H5CH), 3.95 (d, J = 14.3 Hz, 1H, C H5CH ), 3.77
(m, 2H, CH CH CH ), 0.87–0.84 (t, J = 7.3 Hz, 3H, CH ); C NMR
6
6
2
2 2 3
3
(
d, J = 14.3 Hz, 1H, C H5CH ), 3.06–3.03 (m, 1H, CHCHO), 1.43 (d,
(100 MHz, CDCl , ppm): ı 198.7, 138.2, 137.3, 128.9, 128.4, 128.2,
128.1, 127.6, 127.1, 77.3, 71.0, 70.4, 59.3, 37.6, 19.2, 13.9. Enan-
tiomeric ratio was determined by HPLC using Chiracel OJ-RH
6
2
3
1
3
J = 6.2 Hz, 3H, CH ); C NMR (100 MHz, CDCl , ppm): ı 198.6,
1
7
3
3
38.2, 137.2, 129.0, 128.9, 128.5, 128.3, 127.7, 127.2, 73.6, 71.5,
1.2, 59.5, 21.1. Enantiomeric ratio was determined by HPLC using
column after reduction with NaBH /MeOH (70:30 MeOH/H O,
4
2
Chiracel OJ-RH column after reduction with NaBH /MeOH (80:20
1 mL/min flow rate), endo isomers tR = 7.3 min (major enantiomer)
and 6.0 min (minor enantiomer).
4
MeOH/H O, 1 mL/min flow rate), endo isomers tR = 7.1 min (major
2
enantiomer) and 6.4 min (minor enantiomer).
(S)-2-Benzyl-4-formyl-3-phenylisoxazolidine (2g): IR (NaCl):
−
1
1
(4S,
5R)-2-Benzyl-4-formyl-5-methyl-3-(4-chlorophenyl)
ꢀ 2875, 1722, 1495, 1455, 1047 cm
ppm): ı 9.60 (d, J = 3.7 Hz, 1H, CHO), 7.35–7.11 (m, 10H, ArH),
4.12–4.05 (m, 2H, CH ON), 3.93 (d, J = 7.4 Hz, 1H, C H5CH), 3.86
; H NMR (400 MHz, CDCl3,
isoxazolidine (2b): IR (NaCl): ꢀ 2975, 1723, 1493, 1455, 1372,
−
; H NMR (400 MHz, CDCl , ppm): ı 9.65 (d, J = 2.1 Hz,
3
1
1
1
1
090 cm
H, CHO), 7.26–7.16 (m, 9H, ArH), 4.45–4.39 (m, 1H, CHON), 4.07
2
6
(d, J = 14.1 Hz, 1H, C H5CH ), 3.65 (d, J = 14.1 Hz, 1H, C H5CH ),
6
2
6
2
13
(
d, J = 7.4 Hz, 1H, ClC H CH), 3.87 (d, J = 14.2 Hz, 1H, C H5CH ),
3.26–3.24 (m, 1H, CHCHO); C NMR (100 MHz, CDCl , ppm): ı
6
4
6
2
3
3
.75 (d, J = 14.2 Hz, 1H, C H5CH ), 2.92–2.95 (m, 1H, CHCHO), 1.38
198.9, 138.3, 137.4, 129.1, 128.8, 128.4, 128.3, 127.9, 127.4 70.4,
65.9, 64.4, 59.8. Enantiomeric ratio was determined by HPLC using
6
2
1
3
(
d, J = 6.2 Hz, 3H, CH ); C NMR (100 MHz, CDCl , ppm): ı 198.3,
3
3
1
7
37.3, 137.0, 133.8, 129.1, 128.9, 128.3, 127.3, 122.0, 73.6, 71.6,
0.1, 59.7, 21.0. Enantiomeric ratio was determined by HPLC using
Chiracel OJ-RH column after reduction with NaBH /MeOH (70:30
4
MeOH/H O, 1 mL/min flow rate), endo isomers tR = 18.6 min (major
2
Chiracel OJ-RH column after reduction with NaBH /MeOH (80:20
enantiomer) and 20.8 min (minor enantiomer).
4
MeOH/H O, 1 mL/min flow rate), endo isomers tR = 11.2 min (major
2
enantiomer) and 13.2 min (minor enantiomer).
(4S, 5R)-2-Benzyl-4-formyl-5-methyl-3-(4-methoxyphenyl)
isoxazolidine (2c): IR (NaCl): ꢀ 2836, 1723, 1513, 1455, 1303,
3. Results and discussion
−
; H NMR (400 MHz, CDCl , ppm): ı 9.64 (d, J = 2.3 Hz,
3
1
1
1032 cm
H, CHO), 7.26–7.10 (m, 7H, ArH), 6.80 (d, J = 8.8 Hz, 2H,
1
3.1. Catalytic activity of catalyst 1a–c in the 1,3-dipolar
orthoC H OCH ), 4.44–4.38 (m, 1H, CHON), 3.98 (d, J = 8.0 Hz, 1H,
cycloadditions
6
4
3
CH OC H5CH), 3.90 (d, J = 14.5 Hz, 1H, C H5CH ), 3.68–3.65 (m, 4H,
3
6
6
2
OCH , C H5CH ), 2.95–2.99 (m, 1H, CHCHO), 1.39 (d, J = 6.2 Hz, 3H,
To evaluate the capacity of the tetraarylphosphonium supported
chiral imidazolidinones 1a–c in the 1,3-dipolar cycloadditions,
the synthesis of the isoxazolidine aldehyde via N-benzyl-C-phenyl
nitrone with E-crotonaldehyde was chosen as a model reaction.
Then we sought to establish optimal reaction conditions that would
furnish the isoxazolidine aldehyde products 2 and 3 in good yield
and excellent enantioselectivity.
3
6
2
13
CH ); C NMR (100 MHz, CDCl , ppm): ı 198.8, 159.6, 137.5, 129.9,
3
3
1
28.9, 128.8, 128.5, 128.2, 127.1, 114.4, 73.4, 71.5, 70.9, 59.3, 21.2.
Enantiomeric ratio was determined by HPLC using Chiracel OJ-
RH column after reduction with NaBH /MeOH (80:20 MeOH/H O,
4
2
1
mL/min flow rate), endo isomers tR = 7.3 min (major enantiomer)
and 9.5 min (minor enantiomer).
4S, 5R)-2-Benzyl-4-formyl-5-methyl-3-(4-methylphenyl)
isoxazolidine (2d): IR (NaCl): ꢀ 2925, 1724, 1514, 1454, 1372,
(
As illustrated in Table 1, the choice of solvent is found to have a
significant impact on the outcome of the reaction, not only in terms
of yield, but also involve the enantioselectivity (Table 1, entries
1–8). The reactions were carried out in the presence of 20 mol%
−
; H NMR (600 MHz, CDCl , ppm): ı 9.69 (d, J = 2.4 Hz,
3
1
1
1
1
076 cm
H, CHO), 7.26–7.08 (m, 9H, ArH), 4.47–4.43 (m, 1H, CHON), 4.02
◦
(
d, J = 7.9 Hz, 1H, CH C H5CH), 3.92 (d, J = 14.4 Hz, 1H, C H5CH ),
1a/HBF4 combinations in different solvent system at 4–25 C for
3
6
6
2
3
2
.72 (d, J = 14.4 Hz, 1H, C H5CH ), 3.03–3.00 (m, 1H, CHCHO),
24 h. Among the solvents examined, CH NO /H O provided the
best result (entry 8, 82% yield, 94/6 endo/exo, endo 88% ee). There-
6
2
3
2
2
13
.27 (s, 3H, C H CH ), 1.42 (d, J = 6.2 Hz, 3H, OCHCH ); C NMR
6
4
3
3
(
150 MHz, CDCl , ppm): ı 198.5, 137.9, 137.3, 135.1, 129.5, 128.4,
fore, CH NO /H O was chosen as the solvent system to further
3
3
2
2